Clinical Trial Update: A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

A pharmacokinetic and pharmacodynamic study of oral lenalidomide (Revlimid) in patients with low- or intermediate-1-risk myelodysplastic syndromes; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-09-30